



Publication Announcement

Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature

Authors: Gowthami Sai Kogilathota Jagirdhar, Kaanthi Rama, Shiva Teja Reddy, Harsha Pattnaik, Rakhtan K. Qasba (CDRC Social Media Ambassador), Praveen Reddy Elmati, Rahul Kashyap, Marco Schito, and Nitin Gupta.

According to the latest guidelines by the Infectious Disease Society of America (IDSA), there is no defined standard of care for *Acinetobacter baumannii* infections, especially the ones with carbapenem resistant phenotypes. The IDSA guidelines do not comment on the utility of cefoperazone sulbactam since this is an old drug that is no longer available in the US. Despite the limitations of the data (different disease locations, dose variability, treatment duration), single agent treatment was associated with a considerable response in most cases (70% clinical cure on average). Higher quality data systematically captured and standardized through CURE ID should provide a more robust data set to inform trial design and support clinical trials.


[Read more](#)

Meet our Annual Meeting Speakers

**James Robinson**


Professor of Health Economics
University of California, Berkeley

James Robinson is Leonard D. Schaeffer Professor of Health Economics at the University of California at Berkeley. He serves on a variety of professional advisory boards and gives numerous invited speeches for pharmaceutical and technology firms, health insurance plans, hospitals, physician organizations, universities, and public agencies. At Berkeley, Professor Robinson's research focuses on the biotechnology, medical device, insurance, and health care delivery sectors. He has published three books and 150 papers in peer-reviewed journals such as the New England Journal of Medicine, JAMA, and Health Affairs. He teaches classes on public policy, health insurance, and the economics of the life sciences industry.

**Danielle Boyce**

Data scientist, instructor, patient advocate, and researcher
John Hopkins University

Danielle Boyce is a data scientist, instructor, patient advocate, and researcher. She has served on several patient and caregiver advisory panels for the Patient-Centered Outcomes Research Institute, the US Food and Drug Administration as well as academic institutions, pharmaceutical companies, and nonprofits. She currently advises the Centers for Disease Control and Prevention's National ALS Patient Registry and teaches in the Johns Hopkins Biomedical Informatics and Data Science program. Dr. Boyce is lead technical consultant for the CURE Drug Repurposing Collaboratory (CDRC), a public-private partnership of the Critical Path Institute and the US Food and Drug Administration, where she facilitates implementation of the Edge Tool Suite, a package of resources to aid data harmonization to the OMOP common data model, developed by CDRC partners, including Johns Hopkins University and the OHDSI community. Dr. Boyce is the co-founder of the Johns Hopkins OHDSI Research Community and leads the Grants Accelerator initiative which has been awarded 5.41 Million for Hopkins investigators since Oct of 2021 with funding from NSF, NICHD, FDA, and the CDC.

**Marco Schito**

Executive Director
C-Path's CURE Drug Repurposing Collaboratory

Marco Schito is the executive Director of C-Path's CURE Drug Repurposing Collaboratory, the Scientific Director for the Inflammatory Bowel Disease Group, and an Adjunct Professor at the University of Arizona, James E. Rogers College of Law. His work aims to discover potentially safe and effective repurposed therapies for diseases with high unmet medical need by capturing and sharing global, real-world clinical data. Dr. Schito received his PhD from the Ontario Veterinary College at the University of Guelph, Canada in immuno-parasitology.

Save the date

**CURE Drug Repurposing Collaboratory Annual Meeting**
April 18th- 20th, 2023. Hyatt Regency Crystal City

[Register Now!](#)

2799 Richmond Highway - Arlington, Virginia 22202

[Checkout the agenda now](#)

Events

FDA to host 'Clinical Trials: The Patient Experience' workshop

April 13, 2023

The FDA's Center for Biologics Evaluation and Research Office of Therapeutic Products will host a public virtual workshop on April 13 called "Clinical Trials: The Patient Experience," from 11 a.m. to 3 p.m. EDT. The workshop will feature a panel of rare disease patients, caregivers and advocates who will share their experiences with gene therapy clinical trials.

[Read more](#)

FDA to host virtual public meeting 'Patient-Focused Drug Development for Long COVID'

April 25, 2023

On April 25, the FDA is hosting a virtual public meeting called "Patient-Focused Drug Development for Long COVID." The meeting will provide the FDA the opportunity to obtain initial patient and patient representative input on the aspects of long COVID-19, including how it affects their daily life, symptoms that matter most to patients, their current approaches to treating long COVID-19, and what they consider when determining whether or not to participate in a clinical trial. This virtual public meeting will be conducted with live translation in both English and Spanish.


[Register Here.](#)

Trending Articles

[Hyperglycemia Increases Severity of Staphylococcus aureus Osteomyelitis and Influences Bacterial Genes Required for Survival in Bone](#)

[As Superbugs Flourish, Bacteriophage Therapy Recaptures Researchers' Interest](#)

Awareness Month



CURE ID/CDRC Social Media Ambassador

Looking to become a social media ambassador?

CURE ID is looking to recruit individuals interested in help promoting our web-based app. The platform enables healthcare providers to share their real-world experiences treating patients with repurposed drugs. We currently have 20 social media ambassadors and looking to expand.

This is an unpaid position but can win CURE ID/CDRC swag.

This is a competitive opportunity to bring on more followers, tweets, discussion posts, and win some swag!

If interested please reach out to cbassetti@c-path.org



Be Heard

Tell Your Drug Repurposing Story in 2023

Our Impact stories share the value and impact C-Path's and CDRC's work brings to patients, patient organizations, drug developers, the academic community, regulators and more. Enjoy and share! [Impact Stories | Critical Path Institute \(c-path.org\)](#)

Reach out to the Communication and Patient Engagement Manager, Claire Bassetti at cbassetti@cpath.org if interested in sharing your story through an Impact Story.

Joining the CDRC




The CURE Drug Repurposing Collaboratory (CDRC) is a public-private partnership initiated in June 2020 by C-Path and the U.S. Food and Drug Administration (FDA) in partnership with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).

If interested, please feel free to get involved with the CURE Drug Repurposing Collaboratory (CDRC), here: <https://c-path.org/cdrc>

Collaborators



Brought to you by



Visit CURE ID

Visit the CURE ID website for more information.
<https://cure.ncats.io>



Get the CURE ID Mobile App



You received this email because you registered for CURE ID or signed up to receive our monthly newsletter. If you have any questions regarding this communication, please contact us at curesupport@nih.gov